Evidence map›Paper›PMID 36439491›Full record

ArticleFrontiers in oncology2022

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.

Hiroshi Nakatsumi, Yoshito Komatsu, Tetsuhito Muranaka, Satoshi Yuki, Yasuyuki Kawamoto, Kazuaki Harada, Masayoshi Dazai, Miki Tateyama, Yusuke Sasaki, Takuto Miyagishima and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Theranostic role ofEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 1 country.

Hiroshi NakatsumiDepartment of Gastroenterology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
Yoshito KomatsuDivision of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
Tetsuhito MuranakaDepartment of Internal Medicine, Wakkanai City Hospital, Wakkanai, Japan.
Satoshi YukiDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Yasuyuki KawamotoDivision of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
Kazuaki HaradaDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Masayoshi DazaiDepartment of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan.
Miki TateyamaDepartment of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan.
Yusuke SasakiDepartment of Medical Oncology, Hakodate Central General Hospital, Hakodate, Japan.
Takuto MiyagishimaDepartment of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan.
Yasushi TsujiDepartment of Medical Oncology, Tonan Hospital, Sapporo, Japan.
Masaki KatagiriDepartment of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Michio NakamuraDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Susumu SogabeDepartment of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan.
Kazuteru HatanakaDepartment of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan.
Takashi MeguroDepartment of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan.
Tomoe KobayashiDepartment of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan.
Atsushi IshiguroDepartment of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan.
Osamu MutoDepartment of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan.
Yoshiaki ShindoDepartment of Gastroenterological Surgery, Nakadori General Hospital, Akita, Japan.
Masahito KotakaGeneral Cancer Center, Sano Hospital, Kobe, Japan.
Takayuki AndoThe third department of Internal Medicine, University of Toyama, Toyama, Japan.
Ryo TakagiClinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Yu SakataCEO, Misawa Municipal Misawa Hospital, Misawa, Japan.
Hokkaido University Hospital · JPNational Institute of Technology, Tomakomai College · JPNTT Medical Center · JPAkita Red Cross Hospital · JPHakodate Central General Hospital · JPHakodate National Hospital · JPHokkaido hospital · JPKushiro Rosai Hospital · JPMisawa City Hospital · JPNakadōri General Hospital · JPNational Hospital Organization Hokkaido Medical Center · JPSapporo City General Hospital · JPSapporo Hokuyu Hospital · JPTeine Keijinkai Hospital · JPTonan Hospital · JPUniversity of Toyama · JPWakkanai Hokusei Gakuen College · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The first-line chemotherapy for patients with Methods: FOLFIRI (irinotecan 180 mg/m Discussion: There is only an observational study reporting data on FOLFIRI plus AFL for patients with mCRC who previously received anti-EGFR antibodies; therefore, a prospective clinical trial is needed. This study will prospectively evaluate the efficacy and safety of FOLFIRI plus AFL in patients with mCRC who are resistant to anti-EGFR antibodies and have limited data. Moreover, this study will reveal predictive biomarkers for AFL-based chemotherapy. Clinical trial registration: Japan Registry of Clinical Trials, jRCTs011190006. Registered 19 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs011190006.

Indexed as

afliberceptanti-EGFR antibodieschemotherapycolorectal cancerFOLFIRI

Identifiers

PMID36439491
PMCPMC9682015
OpenAlexW4308723141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.